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During tumor evolution, cancer cells use the tumor-stroma crosstalk to reorganize the mi-
croenvironment for maximum robustness of tumor. The success of immune checkpoint 
therapy generates a new cancer therapy paradigm: an effective cancer treatment should not 
aim to influence the individual components of super complex intracellular interactomes 
(molecular targeting), but rather to disrupt the intercellular interactions between cancer and 
stromal cells, thus breaking the tumor as a whole. In this minireview we consider cancer 
associated fibroblasts (CAF) and their interactions with cancer cells as a promising direction 
for cancer therapy.
K e y w o r d s: cancer, hallmark, therapy, immunotherapy, stroma, crosstalk
Abbreviations: CAF — cancer associated fibroblast; ECM — extracellular matrix; TCR — 
T cell receptor; TIL — tumor-infiltrating lymphocyte; TME –tumor microenvironment.
Introduction. Not only Cancer cells 
but their microenvironment is critical 
for tumor progression
In 2000, Hanahan et al. commented that the 
medical implications of the concept of com-
mon hallmarks of cancer are as follows: “We 
envision development of anticancer drugs tar-
geted to each of the hallmark capabilities of 
cancer; some, used in appropriate combina-
tions … will be able to prevent incipient can-
cers from developing, while others will cure 
preexisting cancers, elusive goals at pre-
sent.” [1]. The hallmarks were principally de-
duced for cancer cells, [2, 3], although almost 
all of them, except replicative immortality, 
which is questionable, implicated the participa-
tion of the tumor microenvironment cells [2]. 
Therefore, the concept in this approach implies 
that the therapies act against cancer cells. As 
early as 2006, Orimo and Weinberg noted the 
importance of stroma for tumor progression 
[4]. From approximately 2010, the number of 
publications describing stroma’s contribution 
ISSN 1993-6842 (on-line); ISSN 0233-7657 (print) 
Biopolymers and Cell. 2018. Vol. 34. N 4. P 271–283 
doi: http://dx.doi.org/10.7124/bc.000980
272
I. V. Alekseenko, V. V. Pleshkan, E. D. Sverdlov
to cancer development has quickly increased 
[2, 5, 6], although “abetting microenviron-
ment” has been included in the list of the main 
hallmarks only in 2017 [7].
This inclusion makes sense. The current 
view of the tumor stroma is not just a physical 
support of mutated epithelial cells. All tumors 
engage in a broad repertoire of normal cells in 
their evolution and adopt them for their needs. 
The recruited normal cells facilitate the acqui-
sition of characteristic traits and form what is 
called the tumor microenvironment (TME). 
TME is an ecological niche, which plays the 
most important role in both the development 
of a primary tumor and its metastasi-
zing [2, 8–13].
Neither cancer cells, nor stromal cells alone, 
but their interactions lead to the evolution of 
a tumor as an organ-like entity. These interac-
tions include: (i) direct binary contacts be-
tween ligands and receptors exposed on the 
surfaces of cancer and stroma cells, and (ii) 
paracrine communications between cancer 
(usually epithelial) cells and various cells of 
TME [14, 15] (Fig. 1). Some authors use the 
term “symbiotic” [16, 17] for tumor–stroma 
interaction: “The relationship between tumor 
and stroma is symbiotic. Stromal cells are cor-
rupted by malignant epithelium, creating a 
permissive microenvironment, which drives 
cancer progression” [18] (see also [16, 17]).
It is now clear that to defeat cancer, we 
should move from the indecipherable complex-
ity of intracellular interactomes to disrupting 
the system as a whole by destroying interac-
tions of its parts.
This simple “home-grown intuition” [19] 
determines a new paradigm for cancer therapy: 
the search and destruction of the intercellular 
crosstalk that lies at the root of the success of 
the malignant tumors’ murderous mission.
A stromal component of tumors — an 
indispensable part of cancer evolution
The American National Cancer Institute de-
fines TME as “normal cells, molecules and 
blood vessels that surround and feed a tumor. 
A tumor can change its microenvironment; the 
microenvironment can affect how a tumor 
grows and spreads.” In solid tumors, the can-
cer microenvironment consists of two main 
components, cellular and non-cellular, whose 
ratios and composition vary depending on the 
location and stage of the tumor.
The non-cellular components mainly in-
clude the extracellular matrix (ECM) com-
posed of proteins, glycoproteins, and proteo-
glycans, which serves as a scaffold for sup-
porting tissue architecture [2, 8, 20].
The cellular components include fibroblasts, 
such as cancer associated fibroblasts (CAFs), 
Fig. 1. Direct and paracrine interactions in tumor. Di-
rect binary contacts between antigen-presenting cell and 
T-cell are displayed in example of MHC-antigene-Tcell 
receptor (TCR) and checkpoint molecules (CTLA-4 and 
CD80/86) interactions. Paracrine signaling is presented 
by soluble factors (various circles) and their receptors. 
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mesenchymal stem cells, adipocytes, pericytes, 
endothelial cells, networks of lymphatic ves-
sels, and tumor-infiltrating cells of the immune 
system [18, 21–24]. From the therapeutic point 
of view, immune cell interactions with cancer 
cells might be the most successful targets for 
cancer treatment, and they could serve as a 
paradigm for more general approach.
Immune checkpoint therapy —  
a new paradigm for tumor therapy
T-cells of the immune system have proteins 
on their surface called checkpoints that turn 
on an immune response and other proteins that 
turn it off. Checkpoint proteins activate 
T-cells, for example, when an infection or 
cancer cells is present. However, if T-cells are 
active for too long, or react to things they 
shouldn’t, then other checkpoints switch off 
the T-cells. Some cancer cells make high lev-
els of checkpoint proteins that switch off 
T-cells, so that they can no longer recognize 
and kill cancer cells.
The simple principle of how the T-cells can 
avoid immunosuppression and resume tumor 
annihilation is illustrated in Fig. 2. Monoclonal 
antibodies against CTLA-4 or PD-1, or their 
ligands, disrupt the interaction of these mo le-
cules with T-cells allowing them to destroy 
tumors. This concept was proven by a revolu-
tionary therapeutic success of targeting the 
binary interactions between the stromal im-
mune cells and antigen-presenting cells, stro-
mal immune cells and cancer cells, stromal 
immune cells (CD8+ cytotoxic lymphocytes) 
and CAFs. This kind of therapy was named 
the immune checkpoint therapy.
The most impressive effect of the CTLA-4 
blockade is its ability to induce a long-term 
tumor regression that lasted up to 13 years in 
clinical trials with some melanoma patients. 
However, success rate in the case of mela-
noma was only about 8 % (see the latest data 
in [25]). Moreover, drug-activated T-cells 
affect healthy tissues. Clinical trials revealed 
severe side effects in about 15 % of patients, 
including several fatal outcomes. The reader 
can find the toxicity data in [26]. Still, the 
inhibition of CTLA-4 checkpoint made a 
revolutionary shift in the perception of cancer 
as an incurable disease. The success of im-
munotherapy stimulated the search for other 
inhibiting checkpoints for cancer treat-
ment [27, 28].
Fig. 2. Suppression of T-cell and its activation by 
checkpoint inhibitors. On the upper side the T-cell is 
suppressed by expressed on CAF surface ligands PD-L1/
PD-2 and CD80/86 binding to PD-1 and CTLA-4 recep-
tors of the T-cell, respectively. Lower is demonstrated 
restoration of T-cell activity when blocking antibodies 
(black ancipital fork) to various receptors/ligands are 
present. This disrupts the cell-cell interaction.
274
I. V. Alekseenko, V. V. Pleshkan, E. D. Sverdlov
CTLA-4 and PD-1 regulate different inhi-
biting pathways and have the non-overlapping 
action mechanisms, suggesting that a com-
bined therapy might be more efficient. Indeed, 
this was experimentally demonstrated in pre-
clinical trials with mouse models. The pre-
liminary clinical trials with anti -CTLA-4 
combined with anti-PD-1 or anti-PD-L1 anti-
bodies in other types of tumors produced 
promising results that declare the new com-
bination immunotherapy an efficient strategy 
for cancer patients [27, 29]. However, the 
combined procedure has a somewhat higher 
toxicity.
Although these methods have greatly in-
creased the lifespan of many patients with 
malignant neoplasms, many patients with com-
mon cancer types do not respond to this treat-
ment. Further, inhibition of immune check-
points causes multiple side effects, mostly 
autoimmune inflammatory reactions also 
known as immune-related adverse events 
(IRAEs) [26, 30–32].
Lessons of checkpoint therapy. Inter-
cellular (possibly, synapse-like) con-
tacts vs intracellular interactomes
Cell-surface proteins represent attractive tar-
gets for therapy due to their accessibility and 
involvement in essential signaling pathways, 
often dysregulated in cancer [33]. A receptor-
ligand interaction is in itself a single key 
event — the binding of a signaling molecule 
(ligand) to its receiving molecule (receptor). 
Thus, they are involved in relatively simple 
binary interactions. 
This is the basis of well-recognized drug-
gable properties of receptors and their cognate 
ligands, which make them especially useful 
clinical targets [34]. Furthermore, interacting 
cells in intercellular contacts are brought to-
gether to a distance comparable to the length 
of the receptor-ligand complexes, typically 
15-40 nm [35]. Therefore, inhibition of the two 
targets might also result in the inhibition of 
paracrine crosstalk. 
These considerations lead to a concept of 
therapeutically promising area of direct inter-
cellular interactions as an antithesis of molec-
ular-targeted therapy whose targets are the 
components of complex intracellular interac-
tomes. Immune checkpoint therapy is a strik-
ing example of the success of the above-men-
tioned concept [36]. However, its complexity 
is manifested here by its rather high toxicity 
and the enormous variability of patients’ re-
sponses ranging from none to complete remis-
sion, which presents a challenging problem 
[26, 30, 37, 38].
Worse still, the available long-term follow-
up data on melanoma shows that a substantial 
number of patients that were earlier responding 
to the therapy with inhibitors of immune 
checkpoints become resistant [38, 39]. We do 
not understand why T-cell checkpoints are 
ineffective in the majority of cancer pa-
tients. This could be because their immune 
system does not recognize antigens of cancer 
cells or due to different mechanisms of im-
mune inhibition [40]. 
A multitude of new agents targeting other 
immune and non-immune processes and tumor 
components is under investigation [39]. These 
include inhibitors of immune checkpoints, co-
stimulating agonists, oncolytic viruses, vac-
cines, and adoptive cell therapy, as well as 
combinations with traditional methods of treat-
ment [41]. 
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Other TME components as potential 
participants of cancer stroma 
interaction 
Keeping in mind a successful approach of 
destroying the direct interactions between im-
mune and cancer cells, we hypothesize that a 
similar strategy might be fruitful if such pro-
tumor binary contacts existed between the 
cancer cells and other components of stroma. 
It is widely accepted that paracrine crosstalk 
between tumor stroma cells causes a transfor-
mation of stromal fibroblasts to CAFs. The 
binary contacts between cancer cells and oth-
er components of stroma might be a target for 
therapeutic action. We will give a very concise 
outline of the potentially promising explor-
atory approaches wherein tumor-stroma and 
stroma-stroma interactions can be detected. To 
this end, we will consider an example of CAFs 
which are better studied than the other stromal 
constituents.
A brief overview of cancer-associated 
fibroblasts, barely explored architects 
of cancer pathogenesis
CAFs are some of the most prevalent stromal 
cells in a number of carcinomas, including 
breast, prostate, pancreas, esophagus, and in-
testine cancer [22]. In other carcinomas, in-
cluding ovarian carcinoma, melanomas, and 
kidney tumors, CAFs are less frequent, but still 
occur [8]. CAFs as targets for enhancing can-
cer therapy efficiency attracted great attention. 
Some authors even call them “The Architects 
of Stroma Remodeling” [42] or “Architects of 
Cancer Pathogenesis” [43]. CAFs have been 
reported to variously affect the tumor pro-
gression, involving ECM degradation, re-
lease of numerous soluble factors, regulation 
of tumor metabolism, and promotion of 
cancer cell proliferation, migration, and 
metastasis. The most recent findings are found 
in the relevant reviews [22–24, 42, 44, 45].
The normal fibroblasts can have a variety 
of suppressive functions against the initiation 
of cancer and metastatic cells through direct 
contacts with cells and paracrine signaling 
with soluble factors. The tumor-induced 
transformation of the normal fibroblasts into 
CAFs causes a number of pro-tumorigenic 
signals, followed by a distortion of the normal 
tissue structure, thus supporting the growth of 
cancer cells [46]. CAFs are a heterogeneous 
‘family’ or ‘group’ of cells that exhibit mes-
enchymal-like features. 
Conversion of the normal fibroblasts to 
CAFs is considered a three-step process. First, 
distant normal cells are recruited by malignant 
or pre-malignant cells through paracrine and 
endocrine signals. Second, the recruited cells 
are transformed into CAFs. Finally, the third 
step is the maintenance, expansion and evo-
lution of CAF populations in the cancer mi-
croenvironment, enabled by the persistent sig-
nals produced by malignant cells [47, 48]. In 
return, CAF population emanates paracrine 
signals that affect cancer progression. 
Bidirectional crosstalk between cancer cells 
and fibroblasts is presumed to be the leading 
cause of malignant cancer phenotype forma-
tion [49, 50].
One of the most significant features of CAFs 
is that their phenotype, which promotes tumor 
progression, is stably maintained in vitro and 
ex vivo even without a steady contact with 
neighboring cancer cells [20, 45, 51]. Recent 
studies reported that many types of cells could 
be recruited as predecessors of CAFs: resident 
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tissue fibroblasts, peritumoral adipocytes, bone 
marrow mesenchymal stem cells, hematopoi-
etic stem cells, and many others [44, 45]. After 
recruiting from various sources, a subset of 
these precursors acquires the CAFs phenotype 
through complex activation processes that are 
still poorly understood. Most researches agree 
that irrespective of the precursor, CAFs express 
similar sets of mar kers, such as α-smooth mus-
cle actin (α-SMA), fibroblast activation protein 
(FAP), and the α and β platelet-derived growth 
factor receptor (PDGFR) [44]. Unlike in epi-
thelial cancer cells, the genetic changes such 
as oncogene/tumor suppressor mutations are 
rare in CAFs. In contrast, epigenetic chang-
es, such as DNA methylation, histone modifi-
cations and nucleosome structure, changes in 
the expression of non-coding RNAs and ab-
normal activation of several signaling path-
ways, are often observed when the CAF 
phenotype is acquired. These changes affect 
the expression of many genes encoding growth 
factors, cytokines, and other products which 
intensifies proliferation, stimulates secretion of 
ECM proteins and various growth factors, and 
causes remodeling of cytoskeleton [2, 8, 22, 
44, 45, 52].
Therefore, the stroma currently attracts a 
significant attention of researchers developing 
the new approaches to cancer treatment [5, 21, 
51, 53].
Cancer associated fibroblasts can 
inhibit antitumor immune response 
through direct contact with immune 
cells
Because of their preponderance in the tumor 
microenvironment, CAFs were recently stud-
ied as regulators of immune cell recruitment 
and function. As the result, CAFs were shown 
to play pro-inflammatory and immunosup-
pressive roles through secretion of TGF and 
other cytokines, thus affecting both the in-
nate and adaptive immune response [45, 54]. 
In this review, we will consider direct contact 
of CAFs with cells of the immune system, 
which, in our opinion, are important for 
strengthening and guiding the action of para-
crine factors.
CAFs can establish direct contacts with 
immune cells and affect the efficiency of 
checkpoint immunotherapy by means of the 
expression of co-inhibitory receptor ligands 
[55–58]). By now, such a possibility was ex-
perimentally demonstrated for PD-L1 and/or 
PD-L2 expression. Nazareth and colleagues 
[57] found a constitutively high expression of 
functional PD-L1 and 2 in the fibroblasts cul-
tured from human non-small cell lung cancers. 
It was also shown that CAFs of large intestine 
cancer express PD-L1 and PD-L2 and nega-
tively regulate the proliferative response of 
CD4+ Th-cells. Similar observations were re-
ported for CAFs from melanoma cells (see 
review [45]). However, most of these findings 
were made in in vitro experiments using iso-
lated CAFs, and, therefore, require further 
studies to confirm the physiological signifi-
cance of PD-L1/L2 expression by CAFs for 
their immunosuppressive role in vivo [45]. 
Recent research [55], presents further evi-
dence of the immuno-inhibiting function of 
CAFs resulting from their direct interactions 
with immune cells. The authors show that 
CAFs can function as antigen presenting cells, 
able to absorb, process, and present on their 
surface tumor specific antigens combined with 
MHC-I proteins. With the help of PD-L2 and 
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FASL, this triggers an antigen-specific nega-
tive regulation of tumor-specific CD8+T cells, 
which leads to their dysfunction and apoptosis. 
Neutralization of PD-L2 or FASL reactivates 
the cytotoxic capacity of T cells in vitro and 
in vivo.
Thus, CAFs might support T-cell suppres-
sion within the tumor microenvironment by a 
mechanism dependent on immune checkpoint 
activation. [55], making it another mechanism 
of T-cell depletion and dysfunction within 
tumors [55].
CAFs can directly interact with can-
cer cells and enhance their invasion 
and metastasis
CAFs are often found in the vicinity of, or in 
direct contact with, neoplastic cells [8, 22, 23, 
53]. However, only a few reports provide an 
experimental evidence for the CAF-cancer 
cell direct interaction and study its func-
tional consequences. The most obvious and 
important consequence of such direct interac-
tions is the involvement of CAFs in promot-
ing cancer cell epithelial-mesenchymal tran-
sition, invasion and metastasis [42, 59–64]. 
This should be expected as collective cell mi-
gration is ubiquitous in multicellular organ-
isms. In addition, it is recognized that the 
physical interaction between cells in conjunc-
tion with chemical signals plays a fundamen-
tal role in this process [65].
Gaggioli et al. [59] demonstrated that CAFs 
led the invasion of squamous cell carcinoma 
cells (SCCs) by generating tracks in the extra-
cellular matrix in a co-culture system. During 
joint invasion, the leading cells were CAFs, 
and associated SCC cells followed. Thus, SCC 
cell invasion needs either close proximity, or 
direct contact, to CAFs. Similar evidence is 
presented in the review [63].
To investigate the differential contribution 
of direct cell–cell contacts and paracrine sig-
naling factors to NSCLC metastasis, Choe et 
al. [61] performed two types of co-cultures: 
direct co-cultures of the NSCLC cell line with 
primary cultures of CAFs from patients with 
resected NSCLC and indirect cocultures across 
a separable membrane. CAFs more potently 
induced EMT in case of direct co-culture, 
providing evidence that the physical contacts 
between NSCLC cells and CAFs might control 
the metastatic potential of NSCLC. This prob-
ably does not exclude the participation of para-
crine crosstalk that could be strengthened by 
the physical cell-to-cell interaction, similar to 
the immune synapses.
In a more recent review [42], it is indicated 
that CAFs adjacent to cancer regions were able 
to increase the invasiveness of cancer cells 
through both cell-cell interactions and various 
pro-invasive molecules, such as cytokines, 
chemokines and inflammatory mediators. It is 
also known [42] that CAFs can travel togeth-
er in blood with circulating murine metastatic 
lung carcinoma cancer cells probably support-
ing the cancer cell viability and growth advan-
tage at the metastatic site. The authors hypoth-
esized that in invasive tumors, the cancer and 
stromal cells were in direct contact and estab-
lished a complex crosstalk that evolved during 
tumor development. 
In a very important study [64], the authors 
demonstrated that CAFs caused a collective 
invasion by means of a heterophilic adhesion 
involving N-cadherin at the CAF membrane 
and E-cadherin at the cancer cell membrane. 
Impairment of the E-cadherin/N-cadherin ad-
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hesion abrogates the ability of CAFs to guide 
collective cell migration and blocks cancer cell 
invasion. In parallel, the organizers of intercel-
lular junctions, nectins and afadin, are recruit-
ed to the cancer cell/CAF interface. These 
findings show that a mechanically active het-
erophilic adhesion between CAFs and cancer 
cells enables cooperative tumor inva-
sion. Contacts between cancer cells and CAFs 
may also be implemented through the interac-
tion of Eph-receptor and reciprocal ephrin li-
gands [66]. One can assume that these direct 
contacts form synapse-like structures, strength-
ening the paracrine cross-talk. 
CAFs promote tumor invasion and metas-
tasis. We show that CAFs exert a physical 
force on cancer cells that enables their col-
lective invasion. Force transmission is medi-
ated by a heterophilic adhesion involving 
N-cadherin at the CAF membrane and 
E-cadherin at the cancer cell membrane. 
This adhesion is mechanically active. When 
subjected to force, it triggers β-catenin re-
cruitment and adhesion reinforcement depen-
dent on α-catenin/vinculin interaction. 
Impairment of E-cadherin/N-cadherin adhe-
sion abrogates the ability of CAFs to guide 
collective cell migration and blocks cancer 
cell invasion. N-cadherin also mediates re-
polarization of the CAFs away from the can-
cer cells. In parallel, nectins and afadin are 
recruited to the cancer cell/CAF interface and 
CAF repolarization is afadin dependent. 
Heterotypic junctions between CAFs and can-
cer cells are observed in patient-derived ma-
terial. Together, our findings show that a me-
chanically active heterophilic adhesion be-
tween CAFs and cancer cells enables coop-
erative tumour invasion [64].
Attempts of targeting the interaction 
between CAFs and carcinoma cells
The sinister role of direct interactions of CAFs 
with cancer cells in the process of metastasis 
makes it especially important to destroy these 
contacts for therapeutic purposes. With such a 
goal, Yamaguchi et al. [63] tried to identify 
inhibitors of direct interaction between 
CAFs and cancer cells, and found that the Src 
inhibitor dasatinib effectively blocked the 
physical association between CAFs and scir-
rhous gastric carcinoma (SGC) cells with a 
very low cytotoxic effect. Dasatinib was also 
effective against peritoneal dissemination of 
SGC in mouse model experiments. Importantly, 
histological analysis revealed that metastasiz-
ing tumors were less associated with stromal 
fibroblasts in mice treated with dasatinib com-
pared to controls. These results demonstrate 
that direct interaction between CAFs and 
SGC cells can be a target for anti-metasta-
sis therapy [63]. Nevertheless, the authors 
advise caution, referencing the studies which 
showed that the depletion of CAFs in mouse 
models accelerated progression of pancreatic 
cancer. Although these results are contradic-
tory, they accentuate the need for thorough 
safety testing of the inhibitors of CAF-cancer 
interactions in anticancer therapy. On the oth-
er hand, if the therapeutic target were the CAF-
cancer contacts and not CAFs themselves, the 
strategy might be safe because CAFs would 
not be depleted.
The use of CAF as a trans-shipment 
point for the delivery of genetic thera-
peutic constructs to cancer cells
Another feature of CAFs, important from the 
viewpoint of new therapeutic targets, is worth 
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noting: fibroblasts are more genetically stable 
than “true” cancer cells [21, 67]. They divide 
slowly and, accordingly, slowly mutate. Due 
to this, stromal therapeutic targets might be 
more stable compared to cancer cells with a 
permanently changing genetic structure.
Several strategies have now emerged to 
utilize therapeutic gene delivery to intention-
ally alter the CAFs. It has been shown that 
plasmid DNA can be delivered to, and ex-
pressed in, CAFs using lipid-based nanopar-
ticles as carriers [68, 69]. The delivery of a 
gene that produced a soluble TNFa-related 
apoptosis inducing ligand (sTRAIL) to CAFs 
caused apoptosis in the tumor parenchyma, 
and ultimately tumor regression [69]. Similarly, 
several studies have shown that delivery to 
CAFs of genes encoding fusion proteins de-
signed to be secreted and bound to soluble 
factors such as chemokines and cytokines in 
the tumor microenvironment can cause reduc-
tion of metastasis and ultimately improve sur-
vival in animal models.
Collectively, these results offer a proof of 
concept for the use of gene therapeutic con-
structs to modify CAFs for further transfer of 
therapeutics to cancer cells or their environ-
ment could be an effective strategy to treat 
cancers. 
Conclusion
This review illustrates that cancer is no longer 
regarded just as a set of mutant and dysregu-
lated epithelial cancer cells with their “driver” 
mutations. Instead, cancer and TME (stroma) 
cells jointly form an evolving, integrated, 
cooperative, and dynamic organ-like system. 
So, it becomes clear that in order to defeat 
cancer, we should abandon the attempts to 
treat by targeting the components of complex 
intracellular interactoms, and instead try to 
disrupt the system, as a whole, by destroying 
the interaction of its constituent parts. Further 
analysis of interactions and the development 
of systems for the delivery and expression of 
genes in CAF may lead to the emergence of 
a new approach that will significantly improve 
cancer therapy, especially in combination with 
checkpoint immunotherapy and more tradi-
tional methods such as chemo- and radio-
therapy
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Взаємодії пухлина-строма як мішень 
для протипухлинної терапії
І. В. Алексеєнко, В. В. Плешкан,  
Є. Д. Свердлов
В ході еволюції пухлини ракові клітини використову-
ють взаємодії пухлина-строма для реорганізації мікро-
оточення для досягнення максимальної стійкості пух-
лини. Успіх терапії з використанням імунних контр-
ольних точок запропонував нову парадигму лікування 
раку: для перемоги раку, слід відмовитися від спроб 
його лікування, націлюючись лише на ракові, або 
тільки на стромальні клітини, або на компоненти 
складних внутрішньоклітинних взаємодій. Замість 
цього потрібно докладати зусиль для руйнування пух-
лини в цілому, розірвавши взаємодії між її частинами, 
зокрема, шляхом впливу на прямі контакти між власне 
раковими і стромальних клітинами пухлини. У цьому 
міні-огляді ми розглянемо можливість використання 
пухлина-асоційованих фібробластів (ОАФ) і їхню вза-
ємодію з раковими клітинами як перспективний на-
прям терапії раку.
К л юч ов і  с л ов а: рак, маркер, терапія, імунотера-
пія, строма, взаємодії
283
Cancer–stroma interactions as a target for cancer treatment
Взаимодействия опухоль-строма как мишень 
для противоопухолевой терапии
И. В. Алексеенко, В. В. Плешкан, Е. Д. Свердлов 
В ходе эволюции опухоли раковые клетки используют 
взаимодействия опухоль-строма для реорганизации 
микроокружения с целью достижения максимальной 
устойчивости опухоли. Успех терапии с использованием 
иммунных контрольных точек породил новую 
парадигму лечения рака. Для того, чтобы победить рак, 
следует отказаться от попыток его лечения, нацелива-
ясь только на раковые, или только на стромальные 
клетки, или на компоненты сложных внутриклеточных 
взаимодействий. Вместо этого нужно предпринимать 
усилия для разрушения опухоли в целом, разорвав 
взаимодействия между ее частями, в частности, путем 
воздействия на прямые контакты между собственно 
раковыми и стромальными клетками опухоли. В этом 
мини-обзоре мы рассмотрим возможность использо-
вания опухоль-ассоциированных фибробластов (ОАФ) 
и их взаимодействий с раковыми клетками в качестве 
перспективного направления терапии рака.
К л юч е в ы е  с л ов а: рак, маркер, терапия, иммуно-
терапия, строма, взаимодействия
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